Functional Imaging and Assessment of Antitumor Activity in Systemic Therapy for Hepatocellular Carcinoma.


Hepatocellular carcinoma (HCC) remains the third-leading cause of cancer mortality worldwide and several reports show a rising incidence and mortality rates in several countries over the past decade.1,2 Although the reasons for the changing trends are multifactorial, these are mostly related to changing prevalence of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, alcohol-related liver cirrhosis, diabetes, and obesity, aflatoxins, and tobacco smoking.1,3 Moreover, early diagnosis and improved screening has led to the detection of early-stage HCC. Imaging is central to diagnosis and management of patients with HCC. The therapeutic options currently available for curative therapy in early-stage HCC include liver transplantation, surgical resection, and locoregional therapies such as percutaneous ablation. However, themajorityof patientswithHCC present with advanced disease at the time of diagnosis and long wait time for liver transplantation limits curative therapies for a significant portion of patients.4 Over the past decade, molecularly targeted agents such as antiangiogenic and other target therapies have been increasingly used in the management of patients with advanced HCC.5 Novel tyrosine kinase inhibitors such as sorafenib and regorafenib have been shown to improve median survival in first-line and second-line advanced HCC, respectively.6–8 The recently

DOI: 10.1055/s-0037-1606254

7 Figures and Tables

Cite this paper

@article{Kambadakone2017FunctionalIA, title={Functional Imaging and Assessment of Antitumor Activity in Systemic Therapy for Hepatocellular Carcinoma.}, author={Avinash R Kambadakone and Vinit Baliyan and Andrew X. Zhu}, journal={Seminars in liver disease}, year={2017}, volume={37 3}, pages={259-274} }